search
Back to results

Transgender Estradiol Affirming Therapy (TREAT)

Primary Purpose

Transgenderism

Status
Recruiting
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Transdermal patch
Pro-thrombotic markers
Metabolic markers
Hormone Profile
Sublingual Tablet
Sublingual Tablet
Spironolactone
Sponsored by
Washington University School of Medicine
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Transgenderism focused on measuring Transgender female, Gender affirming hormone therapy, Estrogen therapy

Eligibility Criteria

18 Years - 30 Years (Adult)MaleAccepts Healthy Volunteers

Inclusion Criteria:

  • Female transgender patients between the ages of 18 to 30 years of age who are seen at the Washington University Transgender Center. Patients must have met the eligibility and readiness criteria for gender-affirming hormone therapy.

Exclusion Criteria:

  • GnRH agonist for the last 12 months
  • History of liver disease
  • Dyslipidemia requiring treatment
  • Cigarette smoking
  • Body mass index >30 kg/m2

Sites / Locations

  • Washington University Transgender CenterRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Active Comparator

Active Comparator

Active Comparator

Arm Label

Transdermal estradiol plus spironolactone

Daily sublingual estradiol plus spironolactone

Twice daily sublingual estradiol plus spironolactone

Arm Description

Starting dose will be 100 mcg/24hrs Plan to increase by 100 mcg/24hrs every month to a max dose of 400 mcg/24hrs Goal is to achieve a serum estradiol level between 100-200 pg/mL and to suppress testosterone to cisgender female levels All patients will also receive spironolactone. Spironolactone will be started at 50 mg daily and will increase to standard dose.

Starting dose will be 2 mg daily Plan to increase every month by 2 mg daily Goal is to achieve serum estradiol level between 100-200 pg/mL mL and to suppress testosterone to cisgender female levels. All patients will also receive spironolactone. Spironolactone will be started at 50 mg daily and will increase to standard dose. Spironolactone will be started at 50 mg daily and will increase to standard dose.

Starting dose will be 1 mg twice daily Plan to increase every month by 2 mg daily divided BID Goal is to achieve serum estradiol level between 100-200 pg/mL mL and to suppress testosterone to cisgender female levels All patients will also receive spironolactone. Spironolactone will be started at 50 mg daily and will increase to standard dose. Spironolactone will be started at 50 mg daily and will increase to standard dose.

Outcomes

Primary Outcome Measures

Degree of testosterone suppression by measuring total testosterone level in transgender female patients undergoing hormonal affirming therapy

Secondary Outcome Measures

Coagulation factors II, IX, XI, Protein C, Protein S, von Willebrand factor, and activated protein C resistance in transgender female patients undergoing
von Willebrand factor in transgender female patients undergoing
Llipid panel
Homeostatic Model Assessment for Insulin Resistance

Full Information

First Posted
July 16, 2021
Last Updated
December 2, 2022
Sponsor
Washington University School of Medicine
search

1. Study Identification

Unique Protocol Identification Number
NCT05010707
Brief Title
Transgender Estradiol Affirming Therapy
Acronym
TREAT
Official Title
Effectiveness and Safety of Different Estradiol Replacement Therapies in Transgender Female
Study Type
Interventional

2. Study Status

Record Verification Date
December 2022
Overall Recruitment Status
Recruiting
Study Start Date
August 2, 2021 (Actual)
Primary Completion Date
January 2024 (Anticipated)
Study Completion Date
January 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Washington University School of Medicine

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of this open label, pilot, randomized clinical trial is to evaluate the effectiveness, safety and tolerability of estrogen use in transgender female and the degree of testosterone suppression achieved in this population when placed on gender affirming pharmacological therapy.
Detailed Description
Transgender patients suffer from poor mental and medical health outcomes compared to their cisgender peers. Given the widespread acknowledgment of the health care needs of transgender people, priority should be given to those actions that will ensure safe and appropriate care in health centers. The current hormone therapy is not uniform and depends on the health care system, cost considerations, and differences in the regional availability of estrogens and antiandrogens. A typical regimen includes estrogen to provide feminizing effects in conjunction with therapy to block testosterone (antiandrogens or gonadotropin-releasing hormone [GnRH] analogs). Estrogen also inhibits testosterone secretion. Ethinyl estradiol was previously the mainstay of most estrogen-directed therapies; this is no longer the case due to its increased risk of cardiovascular death and increased incidence of deep venous thrombosis. 17-beta estradiol, which can be provided in tablet, patch, and injection, is currently the preferred formulation. This open label, pilot, randomized clinical trial will evaluate the effectiveness and safety of gender affirming hormone therapy with estrogen and the degree of testosterone suppression achieved in transgender female patients when placed on daily sublingual 17-beta estradiol, twice daily sublingual 17-beta estradiol, or transdermal 17-beta estradiol. All patients will also receive spironolactone as antiandrogen. One of the major complications from estradiol GAHT is thromboembolism. The investigators will also determine the effects of the different estradiol regimens on thrombosis markers. These studies will be the first to determine if the dosing regimen of estradiol affects risk markers in transgender women.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Transgenderism
Keywords
Transgender female, Gender affirming hormone therapy, Estrogen therapy

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Model Description
Participants who agreed to be in the study will undergo block randomization into three groups: daily sublingual 17 beta estradiol twice daily sublingual 17 beta estradiol transdermal 17 beta estradiol All patients will also receive spironolactone as antiandrogen.
Masking
None (Open Label)
Allocation
Randomized
Enrollment
100 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Transdermal estradiol plus spironolactone
Arm Type
Active Comparator
Arm Description
Starting dose will be 100 mcg/24hrs Plan to increase by 100 mcg/24hrs every month to a max dose of 400 mcg/24hrs Goal is to achieve a serum estradiol level between 100-200 pg/mL and to suppress testosterone to cisgender female levels All patients will also receive spironolactone. Spironolactone will be started at 50 mg daily and will increase to standard dose.
Arm Title
Daily sublingual estradiol plus spironolactone
Arm Type
Active Comparator
Arm Description
Starting dose will be 2 mg daily Plan to increase every month by 2 mg daily Goal is to achieve serum estradiol level between 100-200 pg/mL mL and to suppress testosterone to cisgender female levels. All patients will also receive spironolactone. Spironolactone will be started at 50 mg daily and will increase to standard dose. Spironolactone will be started at 50 mg daily and will increase to standard dose.
Arm Title
Twice daily sublingual estradiol plus spironolactone
Arm Type
Active Comparator
Arm Description
Starting dose will be 1 mg twice daily Plan to increase every month by 2 mg daily divided BID Goal is to achieve serum estradiol level between 100-200 pg/mL mL and to suppress testosterone to cisgender female levels All patients will also receive spironolactone. Spironolactone will be started at 50 mg daily and will increase to standard dose. Spironolactone will be started at 50 mg daily and will increase to standard dose.
Intervention Type
Drug
Intervention Name(s)
Transdermal patch
Intervention Description
Participants will be prescribed the medication and dosed based on their hormonal profile. Goal is achieve estradiol level between 100-200 pg/mL and to suppress testosterone to cisgender female levels
Intervention Type
Diagnostic Test
Intervention Name(s)
Pro-thrombotic markers
Intervention Description
Once participants are started on gender affirming hormone therapy, pro-thombotic markers will be checked at baseline and every 6 months. Pro-thrombotic markers will include: Factor II, Factor IX, Factor XI, Von Willebrand factor, Protein C, Protein S, activated Protein C resistance.
Intervention Type
Diagnostic Test
Intervention Name(s)
Metabolic markers
Intervention Description
Once participants are started on gender affirming hormone therapy, metabolic markers will be checked at baseline and every 6 months. Markers will include: Insulin level, fasting glucose, body mass index, waist circumference.
Intervention Type
Diagnostic Test
Intervention Name(s)
Hormone Profile
Intervention Description
Once participants are started on gender affirming hormone therapy, hormonal levels will be checked every 4 weeks until estradiol and testosterone levels are within goal as established by standard of care.
Intervention Type
Drug
Intervention Name(s)
Sublingual Tablet
Other Intervention Name(s)
Once daily dosing
Intervention Description
Participants will be prescribed the medication and dosed based on their hormonal profile. Participants will take dose as once daily medication. Goal is achieve estradiol level between 100-200 pg/mL and to suppress testosterone to cisgender female levels
Intervention Type
Drug
Intervention Name(s)
Sublingual Tablet
Other Intervention Name(s)
Twice daily dosing
Intervention Description
Participants will be prescribed the medication and dosed based on their hormonal profile. Participants will take dose as twice daily medication. Goal is achieve estradiol level between 100-200 pg/mL and to suppress testosterone to cisgender female levels
Intervention Type
Drug
Intervention Name(s)
Spironolactone
Intervention Description
All patients will also receive spironolactone. Spironolactone will be started at 50 mg daily and will increase to standard dose.
Primary Outcome Measure Information:
Title
Degree of testosterone suppression by measuring total testosterone level in transgender female patients undergoing hormonal affirming therapy
Time Frame
Change from baseline total testosterone level at 6,12,18, and 24 months
Secondary Outcome Measure Information:
Title
Coagulation factors II, IX, XI, Protein C, Protein S, von Willebrand factor, and activated protein C resistance in transgender female patients undergoing
Time Frame
Change from baseline factor II, IX, XI, Protein C, Protein S, von Willebrand factor, and activated protein C resistance level at 6,12,18, and 24 months
Title
von Willebrand factor in transgender female patients undergoing
Time Frame
Change from baseline von Willebrand factor antigen level at 6,12,18, and 24 months
Title
Llipid panel
Time Frame
Changes from baseline lipid panel at 12 and 24 months
Title
Homeostatic Model Assessment for Insulin Resistance
Time Frame
Change from baseline HOMA-IR at 6,12,18, and 24 months

10. Eligibility

Sex
Male
Gender Based
Yes
Gender Eligibility Description
Female gender identity
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
30 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Female transgender patients between the ages of 18 to 30 years of age who are seen at the Washington University Transgender Center. Patients must have met the eligibility and readiness criteria for gender-affirming hormone therapy. Exclusion Criteria: GnRH agonist for the last 12 months History of liver disease Dyslipidemia requiring treatment Cigarette smoking Body mass index >30 kg/m2
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Samuel Cortez, MD
Phone
314-286-2339
Email
scortez@wustl.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Ginger Nicol, MD
Organizational Affiliation
Washington University School of Medicine
Official's Role
Principal Investigator
Facility Information:
Facility Name
Washington University Transgender Center
City
Saint Louis
State/Province
Missouri
ZIP/Postal Code
63112
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Samuel Cortez, MD
Phone
314-286-2339
Email
scortez@wustl.edu

12. IPD Sharing Statement

Citations:
PubMed Identifier
28078219
Citation
Unger CA. Hormone therapy for transgender patients. Transl Androl Urol. 2016 Dec;5(6):877-884. doi: 10.21037/tau.2016.09.04.
Results Reference
background
PubMed Identifier
29535563
Citation
Kaltiala-Heino R, Bergman H, Tyolajarvi M, Frisen L. Gender dysphoria in adolescence: current perspectives. Adolesc Health Med Ther. 2018 Mar 2;9:31-41. doi: 10.2147/AHMT.S135432. eCollection 2018.
Results Reference
background
PubMed Identifier
27544457
Citation
Connolly MD, Zervos MJ, Barone CJ 2nd, Johnson CC, Joseph CL. The Mental Health of Transgender Youth: Advances in Understanding. J Adolesc Health. 2016 Nov;59(5):489-495. doi: 10.1016/j.jadohealth.2016.06.012. Epub 2016 Aug 17.
Results Reference
background
PubMed Identifier
31027544
Citation
Hamidi O, Davidge-Pitts CJ. Transfeminine Hormone Therapy. Endocrinol Metab Clin North Am. 2019 Jun;48(2):341-355. doi: 10.1016/j.ecl.2019.02.001. Epub 2019 Mar 23.
Results Reference
background
PubMed Identifier
21266549
Citation
Asscheman H, Giltay EJ, Megens JA, de Ronde WP, van Trotsenburg MA, Gooren LJ. A long-term follow-up study of mortality in transsexuals receiving treatment with cross-sex hormones. Eur J Endocrinol. 2011 Apr;164(4):635-42. doi: 10.1530/EJE-10-1038. Epub 2011 Jan 25.
Results Reference
background
PubMed Identifier
32926454
Citation
Angus LM, Nolan BJ, Zajac JD, Cheung AS. A systematic review of antiandrogens and feminization in transgender women. Clin Endocrinol (Oxf). 2021 May;94(5):743-752. doi: 10.1111/cen.14329. Epub 2020 Oct 5.
Results Reference
background
PubMed Identifier
32180895
Citation
Spanos C, Bretherton I, Zajac JD, Cheung AS. Effects of gender-affirming hormone therapy on insulin resistance and body composition in transgender individuals: A systematic review. World J Diabetes. 2020 Mar 15;11(3):66-77. doi: 10.4239/wjd.v11.i3.66.
Results Reference
background
PubMed Identifier
20553380
Citation
Bagot CN, Marsh MS, Whitehead M, Sherwood R, Roberts L, Patel RK, Arya R. The effect of estrone on thrombin generation may explain the different thrombotic risk between oral and transdermal hormone replacement therapy. J Thromb Haemost. 2010 Aug;8(8):1736-44. doi: 10.1111/j.1538-7836.2010.03953.x. Epub 2010 Jun 14.
Results Reference
background
PubMed Identifier
28945902
Citation
Hembree WC, Cohen-Kettenis PT, Gooren L, Hannema SE, Meyer WJ, Murad MH, Rosenthal SM, Safer JD, Tangpricha V, T'Sjoen GG. Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2017 Nov 1;102(11):3869-3903. doi: 10.1210/jc.2017-01658. Erratum In: J Clin Endocrinol Metab. 2018 Feb 1;103(2):699. J Clin Endocrinol Metab. 2018 Jul 1;103(7):2758-2759.
Results Reference
background
PubMed Identifier
12590642
Citation
Bao AM, Liu RY, van Someren EJ, Hofman MA, Cao YX, Zhou JN. Diurnal rhythm of free estradiol during the menstrual cycle. Eur J Endocrinol. 2003 Feb;148(2):227-32. doi: 10.1530/eje.0.1480227.
Results Reference
background

Learn more about this trial

Transgender Estradiol Affirming Therapy

We'll reach out to this number within 24 hrs